Summary of COVID-19 baloxavir studies

1. Lou et al., Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial

20 patient baloxavir late treatment RCT: 20% improved recovery (p=1) and 600% worse viral clearance (p=0.21).
Small late stage RCT with 10 favipiravir, 10 baloxavir marboxil, and 10 control patients in China, showing no significant differences. The single-dose influenza regimen produced plasma levels far below the SARS-CoV-2 EC50.
Oct 2020, European J. Pharmaceutical Sciences, https://www.sciencedirect.com/science/article/pii/S092809872030419X, https://c19p.org/loubm